Non-Alcoholic Fatty Liver Disease (NAFLD): New challenge for general practitioners and important burden for health authorities?

被引:46
作者
Ahmed, Mohamed H. [3 ]
Abu, Emmanuel O. [3 ]
Byrne, Christopher D. [1 ,2 ]
机构
[1] Univ Southampton, Endocrinol & Metab Unit, DOHaD Div, Southampton, Hants, England
[2] Southampton Univ Hosp Trust, Southampton, Hants, England
[3] Southampton Univ Hosp NHS Trust, Dept Chem Pathol, Southampton, Hants, England
关键词
Non-alcoholic Fatty Liver Disease (NAFLD); Cardiovascular diseases (CVDs); Metabolic syndrome; CORONARY-HEART-DISEASE; GAMMA-GLUTAMYL-TRANSFERASE; HEPATIC STEATOSIS; CARDIOVASCULAR-DISEASE; INSULIN-RESISTANCE; METABOLIC SYNDROME; RISK-FACTORS; INCREASED PREVALENCE; NATURAL-HISTORY; STEATOHEPATITIS;
D O I
10.1016/j.pcd.2010.02.004
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Non-Alcoholic Fatty Liver Disease (NAFLD) is the most common cause of hepatic dysfunction encountered in general practice. A large proportion of individuals with type 2 diabetes and the metabolic syndrome develop NAFLD. NAFLD is associated with severe insulin resistance and increased risk of cardiovascular disease and can progress to non-alcoholic steatohepatitis, liver cirrhosis and cancer. Currently the only known effective treatments for NAFLD are lifestyle changes including stable weight loss and a diet low in calories. General practitioners will increasingly play a key role in dealing with this evolving but serious epidemic of NAFLD and associated metabolic complications. However, success will depend on the appropriate systems and mechanisms being in place in primary care and the proper motivation, support and education of the patient. This review provides the primary care physician with: (a) a step-by step guide of how to identify NAFLD, (b) information to exclude common other causes of liver fat accumulation and (c) additional insight into relationships between NAFLD and other conditions such as obesity, cardiovascular disease and type 2 diabetes. (C) 2010 Primary Care Diabetes Europe. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:129 / 137
页数:9
相关论文
共 53 条
[1]   The natural history of nonalcoholic fatty liver disease: A population-based cohort study [J].
Adams, LA ;
Lymp, JF ;
St Sauver, J ;
Sanderson, SO ;
Lindor, KD ;
Feldstein, A ;
Angulo, P .
GASTROENTEROLOGY, 2005, 129 (01) :113-121
[2]  
Ahmed M.H., 2005, The metabolic syndrome, P279
[3]  
AHMED MH, 2007, YEAR LIPID DISORDERS, P3
[4]   Modulation of sterol regulatory element binding proteins (SREBPs) as potential treatments for non-alcoholic fatty liver disease (NAFLD) [J].
Ahmed, Mohamed H. ;
Byrne, Christopher D. .
DRUG DISCOVERY TODAY, 2007, 12 (17-18) :740-747
[5]   Biochemical markers - The road map for the diagnosis of nonalcoholic fatty liver disease [J].
Ahmed, Mohamed H. .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2007, 127 (01) :20-22
[6]   Current treatment of non-alcoholic fatty liver disease [J].
Ahmed, Mohamed H. ;
Byrne, Christopher D. .
DIABETES OBESITY & METABOLISM, 2009, 11 (03) :188-195
[7]   Nonalcoholic fatfy liver disease in Saudi type 2 diabetic subjects attending a medical outpatient clinic [J].
Akbar, DH ;
Kawther, AH .
DIABETES CARE, 2003, 26 (12) :3351-3352
[8]   How common is non-alcoholic fatty liver disease in the Asia-Pacific region and are there local differences? [J].
Amarapurkar, Deepak N. ;
Hashimoto, Estsuko ;
Lesmana, Laurentius A. ;
Sollano, Jose D. ;
Chen, Pei-Jer ;
Goh, Khean-Lee .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2007, 22 (06) :788-793
[9]   Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis [J].
Angulo, P ;
Keach, JC ;
Batts, KP ;
Lindor, KD .
HEPATOLOGY, 1999, 30 (06) :1356-1362
[10]   Prevalence of and risk factors for nonalcoholic fatty liver disease: The Dionysos Nutrition and Liver Study [J].
Bedogni, G ;
Miglioli, L ;
Masutti, F ;
Tiribelli, C ;
Marchesini, G ;
Bellentani, S .
HEPATOLOGY, 2005, 42 (01) :44-52